The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Iberdomide plus dex effective and well tolerated in R/R MM
Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, The Netherlands, discusses data from a current phase I/II clinical trial (NCT02773030) of a novel cereblon E3 ligase modulatory compound (CELMoD), iberdomide (CC-220), in relapsed/refractory multiple myeloma (R/R MM). Results show that iberdomide has notable clinical activity and favorable tolerability in heavily pretreated patients with R/R MM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
